Systemic Inflammation Laboratory (FeverLab), Trauma Research, St. Joseph's Hospital and Medical Center, Phoenix, Arizona 85013, Department of Pathophysiology and Gerontology, Medical School, University of Pecs, Pecs, H-7624, Hungary, Department of Neuroscience, Amgen Inc., Thousand Oaks, California 91320, Department of Pharmacology and Pharmacotherapy, Medical School, University of Pecs, Pecs, H-7624, Hungary, Janos Szentagothai Research Centre, University of Pecs, Pecs, H-7624, Hungary, and Neuroscience Research, Global Pharmaceutical Research and Development, AbbVie Inc., North Chicago, Illinois 60064.
J Neurosci. 2014 Mar 26;34(13):4445-52. doi: 10.1523/JNEUROSCI.5387-13.2014.
The rodent transient receptor potential ankyrin-1 (TRPA1) channel has been hypothesized to serve as a temperature sensor for thermoregulation in the cold. We tested this hypothesis by using deletion of the Trpa1 gene in mice and pharmacological blockade of the TRPA1 channel in rats. In both Trpa1(-/-) and Trpa1(+/+) mice, severe cold exposure (8°C) resulted in decreases of skin and deep body temperatures to ∼8°C and 13°C, respectively, both temperatures being below the reported 17°C threshold temperature for TRPA1 activation. Under these conditions, Trpa1(-/-) mice had the same dynamics of body temperature as Trpa1(+/+) mice and showed no weakness in the tail skin vasoconstriction response or thermogenic response to cold. In rats, the effects of pharmacological blockade were studied by using two chemically unrelated TRPA1 antagonists: the highly potent and selective compound A967079, which had been characterized earlier, and the relatively new compound 43 ((4R)-1,2,3,4-tetrahydro-4-[3-(3-methoxypropoxy)phenyl]-2-thioxo-5H-indeno[1,2-d]pyrimidin-5-one), which we further characterized in the present study and found to be highly potent (IC50 against cold of ∼8 nm) and selective. Intragastric administration of either antagonist at 30 mg/kg before severe (3°C) cold exposure did not affect the thermoregulatory responses (deep body and tail skin temperatures) of rats, even though plasma concentrations of both antagonists well exceeded their IC50 value at the end of the experiment. In the same experimental setup, blocking the melastatin-8 (TRPM8) channel with AMG2850 (30 mg/kg) attenuated cold-defense mechanisms and led to hypothermia. We conclude that TRPA1 channels do not drive autonomic thermoregulatory responses to cold in rodents.
啮齿动物瞬时受体电位锚蛋白-1 (TRPA1) 通道被假设为冷调节中的温度感受器。我们通过在小鼠中删除 Trpa1 基因和在大鼠中使用 TRPA1 通道的药理学阻断来测试这一假说。在 Trpa1(-/-)和 Trpa1(+/+)小鼠中,严重的冷暴露 (8°C) 导致皮肤和深部体温分别降至约 8°C 和 13°C,这两个温度均低于报道的 TRPA1 激活的 17°C 阈值温度。在这些条件下,Trpa1(-/-) 小鼠的体温动态与 Trpa1(+/+) 小鼠相同,并且在尾部皮肤血管收缩反应或对冷的产热反应中没有变弱。在大鼠中,通过使用两种化学上无关的 TRPA1 拮抗剂研究了药理学阻断的作用:先前已被表征的高活性和选择性化合物 A967079,以及相对较新的化合物 43((4R)-1,2,3,4-四氢-4-[3-(3-甲氧基丙氧基)苯基]-2-硫代-5H-茚并[1,2-d]嘧啶-5-酮),我们在本研究中进一步对其进行了表征,发现其具有高活性(对冷的 IC50 约为 8nm)和选择性。在严重冷暴露 (3°C) 前,将两种拮抗剂中的任何一种以 30mg/kg 的剂量经胃给药,均不会影响大鼠的体温调节反应(深部体温和尾部皮肤温度),尽管在实验结束时,两种拮抗剂的血浆浓度均远远超过其 IC50 值。在相同的实验设置中,用 AMG2850(30mg/kg)阻断 melastatin-8 (TRPM8) 通道会减弱冷防御机制并导致体温过低。我们得出结论,TRPA1 通道不会驱动啮齿动物对冷的自主体温调节反应。